Loading stock data…
Polyrizon Ltd. (PLRZ)
$14.68-0.63 (-4.11%)
Market ClosedLast close Jul 24
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Polyrizon Ltd. in the Healthcare sector is trading at $14.68 with a market capitalization of $25M. The stock is currently 19% below its 52-week high of $18.20, remaining 25.8% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | — | — | — |
| Net Income | — | — | — | — | — |
Peer Comparison
JNJUNHPFE
Fundamentals
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a r...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$25.20M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-
Volume
Today's trading volume
114,819
Recent News
Polyrizon shares climb after NASARIX passes key biocompatibility testing (PLRZ)
NASARIX achieves positive biological safety resultsShares of Polyrizon Ltd. (NASDAQ:PLRZ) gained 10% on Friday after the biotechnology company reported successful results from the biocompatibility evaluation programme for its NASARIX Allergy Blocker nasal spray.
This Former Penny Stock Just Doubled for the Second Time This Week. Should You Chase the Rally Here?
Polyrizon shares have skyrocketed this week on breakthrough preclinical data for its naloxone hydrogen. But PLRZ stock remains a risky proposition heading into 2026.
We Think Polyrizon (NASDAQ:PLRZ) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
BC-Most Active Stocks
HIVE Digital Technologies Ltd. 15,939,276 3.3797